Thomson Reuters | Thomson Reuters Forecast

Science

Predicting the commercial potential of a drug is difficult and time consuming if you don’t have the data to support your assumptions. When these data are spread among multiple sources, your task can be time consuming at best, and impossible at worst.

Thomson Reuters Forecast™ gives you the most accurate available method of assessing the sales potential of new drugs by integrating and summarizing multiple perspectives on drugs that will compete with yours.

For each therapeutic franchise, Thomson Reuters Forecast enables you to compare the most significant candidates in the development pipeline and the key drugs that have reached the market. It provides a consensus of analyst forecasts for pipeline and marketed drugs, and downloadable, patient-based revenue models for drugs in more than 100 indications, providing transparent assumptions on incidence and prevalence, eligible numbers of patients, estimated timing of approval, pricing, and market share within the indication.

You can search by drug, franchise or company. More than 3,000 drugs in the pipeline stage are currently monitored, including drugs in Phase III development, with more coming into the database every day.

Thomson Reuters Forecast gives you the data you need to quickly develop forecasts for your pipeline or marketed drug.

With Thomson Reuters Forecast, you can:

Compare the drug you are evaluating to those it will compete with.
Evaluate drug summaries, partnering and development history, upcoming events likely to affect approval, and numerical ratings on likelihood of approval.
Review both consensus analyst market forecasts and transparent, patient-based forecasts for drugs that will compete with yours.
Complete a quick SWOT analysis that outlines a drug opportunity’s Strengths, Weaknesses, Opportunities, and Threats.
Download patient-based forecasts and factor in your assumptions.

Why choose Thomson Reuters Forecast?

Each drug tracked in Thomson Reuters Forecast includes a summary of the drug, including Molecule Type Classification, the company(ies) developing it, the indications and mechanism of action, and links to similar drugs.
Analysts focused exclusively on the pharmaceutical industry give you a head start on quantifying its likelihood of approval. They appraise the scientific, clinical and regulatory catalysts that will affect its progress, and assign and regularly update a likelihood-of-approval score.
It provides a consensus of analyst forecasts for the most strategic drugs in each therapeutic franchise, and downloadable, patient-based revenue models. You can also create reports using franchise revenue graphs, including reported sales, consensus forecast, and proprietary forecast.
Those who also subscribe to Thomson Reuters Partnering Pipeline can access the full drug report, giving you the background information you need to accurately assess the competitive landscape surrounding it, including five years of historical sales data by region, year of last launch, and sales in U.S. millions.

Contact Us

North America

Tel: +1 800.336.4474
Tel: +1 215.386.0100
Fax: +1 215.386.2911

Europe, Middle East & Africa

Tel: +44 20.7433.4000

Latin America

Brazil: +55 11 8370 9845
Other Countries: +1 215 823 5674

Japan

Tel: +81 3.5218.6500
Tel: 0800 888.8855 (free dial from Japan only)
Fax: +81 3.5218.7840

Asia Pacific

Australia & New Zealand:
+61 2 8587 7636
China: +86 10 5760 1200
India: +91 11 3044 6419
Korea: +82 2 2076 8100
South East Asia & Pakistan:
+65 6775 5088
Taiwan: +886 2 2503 3034